LIVALO pitavastatin 4 mg film-coated tablet blister pack

País: Austrália

Língua: inglês

Origem: Department of Health (Therapeutic Goods Administration)

Ingredientes ativos:

pitavastatin calcium, Quantity: 4.18 mg (Equivalent: pitavastatin, Qty 4 mg)

Disponível em:

Advantage Medical Products Consulting Pty Ltd

DCI (Denominação Comum Internacional):

pitavastatin calcium

Forma farmacêutica:

Tablet, film coated

Composição:

Excipient Ingredients: aluminium magnesium silicate; lactose monohydrate; hypromellose; triethyl citrate; magnesium stearate; hyprolose; titanium dioxide; colloidal anhydrous silica

Via de administração:

Oral

Unidades em pacote:

100, 10, 30, 28

Tipo de prescrição:

(S4) Prescription Only Medicine

Indicações terapêuticas:

Livalo is indicated as an adjunct to diet for the treatment of adult patients with primary hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, when response to diet and other non-pharmacological measures is inadequate. Prior to initiating therapy with Livalo, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Resumo do produto:

Visual Identification: Round biconvex white film-coated tablets embossed on one side with 'KC' and '4' on the other side; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Status de autorização:

Licence status A

Data de autorização:

2013-08-27